Chemoprevention of gastric cancer: Role of COX-2 inhibitors and other agents

Digestive Diseases

Volumn 22, Issue 4, 2004, Pages 320-326

  Nardone, Gerardo ^a   Rocco, Alba ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chemoprevention; COX 2 inhibitors; Gastric cancer; Helicobacter pylori

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MELECOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; TILMACOXIB; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ERADICATION THERAPY; GASTROINTESTINAL MUCOSA; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIFESTYLE; LONG TERM CARE; NONHUMAN; PEPTIC ULCER; POPULATION; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH INJURY; UPPER GASTROINTESTINAL TRACT; ANIMAL; DRUG EFFECT; ENZYMOLOGY; HELICOBACTER INFECTION; METABOLISM; STOMACH TUMOR; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIET; HELICOBACTER INFECTIONS; HUMANS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 21844473304     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083593     Document Type: Review

References (71)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
2. American Cancer Society: Estimated New Cancer Cases and Deaths by Sex for all Sites. American Cancer Society, United States, 2000 (table). http://www.cancer.org/statistics/cff2000/data/newCaseSex.html
3. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
4. Sporn MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2689-2702.
5. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH: Aspirin use and colorectal cancer: Post-trial follow-up data from the Physician's Health Study. Ann Intern Med 1998;128:713-20.
6. Vane JR, Bakhle YS, Botting RM: Cyclo-oxygenase 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
7. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304-2312.
8. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-33160.
9. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van de Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
10. Tatsuguchi A, Sakamoto C, Wada K, Akamatsu T, Tsukui T, Miyake K, Futagami S, Kishida T, Fukuda Y, Yamanaka N, Kobayashi M: Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori-related gastritis and gastric ulcer tissues in humans. Gut 2000;46:782-789.
11. L: A molecular pathway of H. pylori-related gastric carcinogenesis. J Pathol 2004;202:305-312.
12. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, Chan FK: Cyclooxygenase-2 expression in Helicobacter pylori-associated pre-malignant and malignant gastric lesions. Am J Pathol 2000;157:729-735.
13. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-1280.
14. Saukkonen K, Nieminen O, van Rees B, Vilkki S, Harkonen M, Juhola M, Mecklin JP, Sipponen P, Ristimaki A: Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-1931.
15. Yamagata R, Shimoyama T, Fukuda S, Yoshimura T, Tanaka M, Munakata A: Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol 2002;14:359-363.
16. Tsuji S, Kawano S, Sawaoka H, Takei Y, Kobayashi I, Nagano K, Fusamoto H, Kamada T: Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 1996;55:179-183.
17. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H, Hori M: Effects of NSAIDs on proliferation of gastric cancer cells in vitro: Possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 1998;27 (suppl 1):47-52.
18. Uefuji K, Ichikura T, Shinomiya N, Mochizuki H: Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res 2000;20:4279-4284.
19. Husain SS, Szabo IL, Pai R, Soreghan B, Jones MK, Tarnawski AS: MAPK (ERK2) kinase - A key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sci 2001;69:3045-3054.
20. Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, Fan DM, Lam SK: Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 2001;22:1393-1397.
21. Li JY, Wang XZ, Chen FL, Yu JP, Luo HS: Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol 2003;9:915-920.
22. 1- dependent pathway. Oncogene 2002;21:6113-6122.
23. Wong BC, Jiang X, Fan XM, Lin MC, Jiang SH, Lam SK, Kung HF: Suppression of RelA/ p65 nuclear translocation independent of IκB-α degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 2003;22:1189-1197.
24. Wu J, Xia HH, Tu SP, Fan DM, Lin MC, Kung HF, Lam SK, Wong BC: 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis 2003;24:243-247.
25. Liu C, Tang C, Wan X, Wang C, Zhou X: The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban 2003;34:480-483.
26. Wang C, Tang C: Inhibition effect of aspirin on the growth of gastric cancer and the mechanism therein involved. Sichuan Da Xue Xue Bao Yi Xue Ban 2003;34:468-71.
27. Leung WK, To KF, Go MY, Chan KK, Chan FK, Ng EK, Chung SC, Sung JJ: Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 2003;23:1317-1322.
28. Hu GY, Yu BP, Yu JP, Ran ZX, Luo HS: Nimesulide, a selective cyclooxygenase-2 inhibitor inhibits telomerase activity by blocking activation of PKB in gastric cancer cell line. Zhonghua Zhong Liu Za Zhi 2004;26:209-212.
29. Moss SF: Cellular markers in the gastric precancerous process. Aliment Pharmacol Ther 1998;12(suppl 1):91-109.
30. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K: Cyclooxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol 2001;ii:544-551.
31. 2 on gastrointestinal tumorigenesis induced by N-methyl-N -nitro-N-nitrosoguanidine in rats. I. Squamous epithelium and mesenchymal tissue. J Natl Cancer Inst 1987;78:923-929.
32. Bespalov VG, Troian DN, Petrov AS, Morozov VG, Khavinson VK: Inhibiting effect of thymogen on the development of tumors of the esophagus and forestomach induced by N-nitrososarcosine ethyl ester in rats. Eksp Onkol 1989;11:23-26.
33. 2 on gastrointestinal tumorigenesis induced by N-methyl-N -nitro-N-nitrosoguanidine in rats: Glandular epithelium of stomach and duodenum. Cancer Res 1990;50:381-384.
34. Jalbert G, Castonguay A: Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett 1992;66:21-28.
35. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K, Hori M: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998;274:G1061-G1067.
36. Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y: Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 2004;10:1971-1974.
37. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai AH, Sung JJ: Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195-200.
38. Thun MJ, Namboodiri MM, Calle EE, Flanders D, Heath CW: Aspirin use and risk of fatal cancer. Cancer Res 1993:1322-1327.
39. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ: Use of aspirin and other non-steroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
40. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V: Aspirin protects against gastric cancer: Results of a case-control study from Moscow, Russia. Int J Cancer 1999;82:473-476.
41. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S: Non-steroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9:119-123.
42. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ: Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ 2000;320:1642-1646.
43. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O: Aspirin and risk for gastric cancer: A population-based case-control study in Sweden. Br J Cancer 2001;84:965-968.
44. Sorensen HT, Friis S, Norgard B, Mellemkjær L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA: Risk of cancer in a large cohort of non-aspirin NSAID users: A population-based study. Br J Cancer 2003;88:1687-1692.
45. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, liver flukes and Helicobacter pylori, Lyon, June 7-14 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
46. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
47. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS, China Gastric Cancer Study Group: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: Randomized controlled trial. JAMA 2004;291:187-194.
48. Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC: Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study. Gastroenterology 2000;119:7-14.
49. Tepes B, Kavcic B, Zaletel LK, Gubina M, Ihan A, Poljak M, Krizman I: Two- to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 1999;188:24-29.
50. Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K: Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: A 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002;16:1449-1456.
51. Genta RM, Franceschi F: Gastric markers of pre-malignancy are not reversible; in Hunt RH, Tytgut GNJ (eds): Helicobacter pylori - Basic Mechanisms to Clinical Cure 2000. Hamilton, Kluwer Academic, 2000, pp 524-534.
52. Franceschi F, Genta RM, Sepulveda AR: Gastric mucosa: Long-term outcome after cure of Helicobacter pylori infection. J Gastroenterol 2002;37:17-23.
53. Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N: Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16:1923-1932.
54. Nardone G, Rocco A, Malfertheiner P: Review article: Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther 2004;20:261-270.
55. Yamaguchi N, Kakizoe T: Synergistic interaction between Helicobacter pylori gastritis and diet in gastric cancer. Lancet Oncol 2001;2:84-94.
56. Zullo A, Rinaldi V, Hassan C, Diana F, Winn S, Castagna G, Attili AF: Ascorbic acid and intestinal metaplasia in the stomach: A prospective, randomised study. Aliment Pharmacol Ther 2000;14:1303-1309.
57. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-1888.
58. Weisburger JH, Chung FL, Weisburger JH, Chung FL: Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. Food Chem Toxicol 2002;40:1145-1154.
59. Ngoan LT, Mizoue T, Fujino Y, Tokui N, Yoshimura T: Dietary factors and stomach cancer mortality. Br J Cancer 2002;87:37.
60. Trichopoulos D, Ouranos G, Day NE, Tzonou A, Manousos O, Papadimitriou C, Trichopoulos A: Diet and cancer of the stomach: A case-control study in Greece. Int J Cancer 1985;36:291-297.
61. Buiatti E, Palli D, Decarli A, Amadori D, Avellini C, Bianchi S, Biserni R, Cipriani F, Cocco P, Giacosa A, et al: A case-control study of gastric cancer and diet in Italy. Int J Cancer 1989;44:611-661.
62. Kono S, Ikeda M, Tokudome S, Kuratsune M: A case-control study of gastric cancer and diet in northern Kyushu, Japan. Jpn J Cancer Res 1988;79:1067-1074.
63. Yu GP, Hsieh CC: Risk factors for stomach cancer: A population-based case-control study in Shanghai. Cancer Causes Control 1991;2:169-174.
64. Fleischauer AT, Poole C, Arab L: Garlic consumption and cancer prevention: Meta-analyses of colorectal and stomach cancers. Am J Clin Nutr 2000;72:1047-1052.
65. Nagata C, Takatsuka N, Kawakami N, Shimizu H: A prospective cohort study of soy product intake and stomach cancer death. Br J Cancer 2002;87:31-36.
66. Kobayashi M, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S: Vegetables, fruit and risk of gastric cancer in Japan: A 10-year follow-up of the JPHC study Cohort I. Int J Cancer 2002;102:39-44.
67. Serafini M, Bellocco R, Wolk A, Ekstrom AM: Total antioxidant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology 2002;123:985-991.
68. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, et al: Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/ mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1492.
69. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, La-Motte F, Gaziano JM, Ridker PM, Willett W, Peto R: Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-1149.
70. Xiao SD, Meng XJ, Shi Y, Hu JB, Zhu SS, Wang CW: Interventional study of high-dose folic acid in gastric carcinogenesis in beagles. Gut 2002;50:61-64.
71. Greenly RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.